Caribou Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	34.48	13.85	9.6	12.36	5.79
Revenue Growth (YoY)	148.91%	44.31%	-22.35%	113.56%	-
Gross Profit	34.48	13.85	9.6	12.36	5.79
Selling, General & Admin	38.46	38.02	24.32	14.06	16.46
Research & Development	112.08	82.23	52.26	34.43	23.64
Operating Expenses	150.54	120.25	76.58	48.49	40.09
Operating Income	-116.06	-106.4	-66.98	-36.12	-34.31
Interest Expense / Income	0	0	0	0.02	0
Other Expense / Income	-14.18	-7.05	-0.38	-0.02	-3.34
Pretax Income	-101.88	-99.35	-66.6	-36.13	-30.97
Income Tax	0.19	0.07	0.32	-1.82	-7.54
Net Income	-102.07	-99.42	-66.92	-34.31	-23.43
Shares Outstanding (Basic)	74	61	32	9	8
Shares Outstanding (Diluted)	74	61	32	9	8
Shares Change	21.39%	92.02%	270.47%	2.05%	-
EPS (Basic)	-1.38	-1.64	-2.11	-4.01	-2.80
EPS (Diluted)	-1.38	-1.64	-2.11	-4.01	-2.80
Free Cash Flow	-104.9	-97.42	-34.64	-33.52	-32.89
Free Cash Flow Per Share	-1.42	-1.60	-1.09	-3.92	-3.93
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-336.63%	-768.17%	-697.84%	-292.24%	-592.69%
Profit Margin	-296.05%	-717.79%	-697.26%	-277.55%	-404.82%
Free Cash Flow Margin	-304.27%	-703.34%	-360.91%	-271.19%	-568.24%
EBITDA	-96.3	-95.71	-65.62	-35.21	-30.21
EBITDA Margin	-279.33%	-691.00%	-683.66%	-284.82%	-521.99%
Depreciation & Amortization	5.57	3.64	0.98	0.9	0.75
EBIT	-101.88	-99.35	-66.6	-36.11	-30.96
EBIT Margin	-295.49%	-717.28%	-693.92%	-292.10%	-534.97%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).